Press releases

19 May, 2021

Regulatory

Abliva reports positive clinical Phase 1a/b results for KL1333 including signs of efficacy in PMD patients

Abliva AB (Nasdaq Stockholm: ABLI), a clinical-stage biopharmaceutical company developing medicines for the treatment of rare and severe primary mitochondrial diseases (PMD), today announced positive ...

30 March, 2021

Regulatory

Abliva has completed a directed new issue

Abliva AB (Nasdaq Stockholm: ABLI) (“Abliva” or “the Company”), a biopharmaceutical company in the clinical phase that develops drugs for the treatment of rare and serious primary mitochondrial diseas ...

30 March, 2021

Regulatory

Abliva investigates the prerequisites for carrying out a directed new issue

Abliva AB (Nasdaq Stockholm: ABLI) (“Abliva” or the “Company”) a clinical-stage biopharmaceutical company developing medicines for the treatment of rare and severe primary mitochondrial diseases, toda ...

20 January, 2021

Regulatory

Abliva appoints Ellen Donnelly as new CEO as it enters a new stage in its development

Abliva AB (Nasdaq Stockholm: ABLI), a clinical-stage biopharmaceutical company developing medicines for the treatment of rare and severe primary mitochondrial diseases, today announced that the Board ...

9 September, 2020

Regulatory

Abliva intends to start a pivotal KL1333 study second half 2021

Abliva AB (Nasdaq Stockholm: ABLI) today announced that the company’s Board of Directors has decided to accelerate the KL1333 clinical program, with the intention to start a pivotal Phase II/III clini ...

5 May, 2020

Regulatory

NeuroVive publishes outcome in rights issue

NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP) (”NeuroVive” or the ”Company”) today announces that the new share issue with preferential rights for existing shareholders, announced by the Company ...

22 April, 2020

Regulatory

NeuroVive makes a MSEK 20 directed share issue to leading Nordic life science investor Hadean Ventures

NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP) (”NeuroVive” or the ”Company”) has today decided upon a directed issue of shares totaling around MSEK 20 to Hadean Ventures (“Directed Issue”). Hade ...

19 February, 2020

Regulatory

NeuroVive proposes a rights issue of MSEK 74 and accelerates the clinical development of KL1333

Lund, Sweden, 19 February 2020, NeuroVive Pharmaceutical AB (Nasdaq Stockholm) today announced that the Board of Directors of NeuroVive Pharmaceutical AB (publ) ("NeuroVive" or the "Company") has reso ...

16 December, 2019

Regulatory

NeuroVive announces settlement in dispute with CicloMulsion AG

Lund, Sweden, 16 December 2019, NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) announced today that it has fully and finally settled the dispute with CicloMulsion AG regarding certa ...

27 July, 2019

Regulatory

NeuroVive’s NeuroSTAT project receives FDA Fast Track designation

Lund, Sweden, 27 July 2019, NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) today announced that the company's candidate drug NeuroSTAT, in development for treatment of moderate to s ...

4 July, 2019

Regulatory

NeuroVive initiates second part of its ongoing KL1333 Phase Ia/b clinical study

Lund, Sweden, 4 July 2019, NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) today announced that the company has initiated the second part in its ongoing Phase Ia/b clinical study wit ...

10 May, 2019

Regulatory

NeuroVive’s IND for clinical development of NeuroSTAT approved by FDA

Lund, Sweden,10 May 2019, NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) today announced that the US Food and Drug Administration, FDA, has approved NeuroVive's IND (Investigational ...